Clinical efficacy of the combination of atorvastatin and perindopril in prevention of cardiovascular outcomes and mortality among high-risk hypertensive patients randomized to the ASCOT-LLA trial
Queen Mary University of London, London (United Kingdom of Great Britain & Northern Ireland)
2
presentations
0
follower
7
more
presentations
in this session
Effects of empagliflozin on cardiac and vascular hemodynamic markers by subgroups of age, sex and hypertension in patients with T2DM and high CV risk: EMPA-reg outcome.
Monocyte chemoattractant protein-1 level and (-75)G/A polymorphism of APOA1 gene predict response and resistance to intensive statin therapy in very high cardiovascular risk patients.
Speaker:
Professor S. Villevalde (Saint Petersburg, RU)
Efficacy of evinacumab in homozygous familial hypercholesterolemia patients with null or non-null LDL-receptor mutations and on various background therapies